|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cardoso F, Paluch-Shimon S, Senkus E,
Curigliano G, Aapro MS, André F, Barrios CH, Bergh J, Bhattacharyya
GS, Biganzoli L, et al: 5th ESO-ESMO international consensus
guidelines for advanced breast cancer (ABC 5). Ann Oncol.
31:1623–1649. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li CI, Uribe DJ and Daling JR: Clinical
characteristics of different histologic types of breast cancer. Br
J Cancer. 93:1046–1052. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Burstein HJ, Curigliano G, Thürlimann B,
Weber WP, Poortmans P, Regan MM, Senn HJ, Winer EP and Gnant M;
Panelists of the St Gallen Consensus Conference, : Customizing
local and systemic therapies for women with early breast cancer:
The St. gallen international consensus guidelines for treatment of
early breast cancer 2021. Ann Oncol. 32:1216–1235. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rechsteiner A, Dietrich D and Varga Z:
Prognostic relevance of mixed histological subtypes in invasive
breast carcinoma: A retrospective analysis. J Cancer Res Clin
Oncol. 149:4967–4978. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sherwani M, Vohra L, Ali D, Soomro R,
Adnan S and Idrees R: Clinicopathological features and survival
outcomes of metaplastic breast carcinoma-an observational
multi-centric study. Breast Cancer (Dove Med Press). 15:237–250.
2023.PubMed/NCBI
|
|
7
|
McCart Reed AE, Kalaw EM and Lakhani SR:
An update on the molecular pathology of metaplastic breast cancer.
Breast Cancer (Dove Med Press). 13:161–170. 2021.PubMed/NCBI
|
|
8
|
Wong W, Brogi E, Reis-Filho JS, Plitas G,
Robson M, Norton L, Morrow M and Wen HY: Poor response to
neoadjuvant chemotherapy in metaplastic breast carcinoma. NPJ
Breast Cancer. 7:962021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ismail Y, Kamal A, Allam R and Zakaria AS:
The conundrum of metaplastic breast cancer: A single Egyptian
institution retrospective 10-year experience (2011–2020). J Egypt
Natl Canc Inst. 35:162023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lan T, Lu Y, Zheng R, Shao X, Luo H, He J,
Yang H, Xu H, Wang X and Hu Z: The role of adjuvant chemotherapy in
metaplastic breast carcinoma: A competing risk analysis of the SEER
database. Front Oncol. 11:5722302021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Barnes PJ, Boutilier R, Chiasson D and
Rayson D: Metaplastic breast carcinoma: Clinical-pathologic
characteristics and HER2/neu expression. Breast Cancer Res Treat.
91:173–178. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Papatheodoridi A, Papamattheou E,
Marinopoulos S, Ntanasis-Stathopoulos I, Dimitrakakis C, Giannos A,
Kaparelou M, Liontos M, Dimopoulos MA and Zagouri F: Metaplastic
carcinoma of the breast: Case series of a single institute and
review of the literature. Med Sci (Basel). 11:352023.PubMed/NCBI
|
|
13
|
Nowara E, Drosik A, Samborska-Plewicka M,
Nowara EM and Stanek-Widera A: Metaplastic breast
carcinomas-analysis of prognostic factors in a case series. Contemp
Oncol (Pozn). 18:116–119. 2014.PubMed/NCBI
|
|
14
|
Xu D and Hou L: Clinicopathologic
characteristics of mixed epithelial/mesenchymal metaplastic breast
carcinoma (carcinosarcoma): A meta-analysis of Chinese patients.
Pol J Pathol. 70:174–182. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lai HW, Tseng LM, Chang TW, Kuo YL, Hsieh
CM, Chen ST, Kuo SJ, Su CC and Chen DR: The prognostic significance
of metaplastic carcinoma of the breast (MCB)-a case controlled
comparison study with infiltrating ductal carcinoma. Breast.
22:968–973. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cimino-Mathews A, Verma S,
Figueroa-Magalhaes MC, Jeter SC, Zhang Z, Argani P, Stearns V and
Connolly RM: A clinicopathologic analysis of 45 patients with
metaplastic breast carcinoma. Am J Clin Pathol. 145:365–372. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chaudhary D, Balhara K, Mandal S, Mallya
V, Tomar R, Khurana N and Bains L: Metaplastic breast carcinoma:
Analysis of clinical and pathologic features, a five-year study. J
Cancer Res Ther. 19:1226–1230. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang Y, Lv F, Yang Y, Qian X, Lang R, Fan
Y, Liu F, Li Y, Li S, Shen B, et al: Clinicopathological features
and prognosis of metaplastic breast carcinoma: Experience of a
major Chinese cancer center. PLoS One. 10:e01314092015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Leyrer CM, Berriochoa CA, Agrawal S,
Donaldson A, Calhoun BC, Shah C, Stewart R, Moore HCF and Tendulkar
RD: Predictive factors on outcomes in metaplastic breast cancer.
Breast Cancer Res Treat. 165:499–504. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ishizuka Y, Horimoto Y, Yanagisawa N,
Arakawa A, Nakai K and Saito M: Clinicopathological examination of
metaplastic spindle cell carcinoma of the breast: Case series.
Breast Cancer (Auckl). 15:117822342110394332021.PubMed/NCBI
|
|
21
|
Ghosh M, Muneer A, Trivedi V, Mandal K and
Shubham S: Metaplastic carcinoma breast: A clinical analysis of
nine cases. J Clin Diagn Res. 11:XR01–XR03. 2017.PubMed/NCBI
|
|
22
|
Salimoğlu S, Sert İ, Emiroğlu M, Karaali
C, Kuzukıran D, Kırmızı YA, Diniz G and Aydın C: Metaplastic breast
carcinoma: Analysis of clinical and pathologic characteristics-a
case series. J Breast Health. 12:63–66. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rakha EA, Tan PH, Varga Z, Tse GM, Shaaban
AM, Climent F, van Deurzen CH, Purnell D, Dodwell D, Chan T and
Ellis IO: Prognostic factors in metaplastic carcinoma of the
breast: A multi-institutional study. Br J Cancer. 112:283–289.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xiao M, Yang Z, Tang X, Mu L, Cao X and
Wang X: Clinicopathological characteristics and prognosis of
metaplastic carcinoma of the breast. Oncol Lett. 14:1971–1978.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thapa B, Arobelidze S, Clark BA, Xuefei J,
Daw H, Cheng YC, Patel M, Spiro TP and Haddad A: Metaplastic breast
cancer: Characteristics and survival outcomes. Cureus.
14:e285512022.PubMed/NCBI
|
|
26
|
Damera VV, Chowdhury Z, Tripathi M, Singh
R, Verma RK and Jain M: Clinicopathologic features of metaplastic
breast carcinoma: Experience from a tertiary cancer center of North
India. Cureus. 14:e289782022.PubMed/NCBI
|
|
27
|
McMullen ER, Zoumberos NA and Kleer CG:
Metaplastic breast carcinoma: Update on histopathology and
molecular alterations. Arch Pathol Lab Med. 143:1492–1496. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Basho RK, Yam C, Gilcrease M, Murthy RK,
Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V,
Albarracin C, et al: Comparative effectiveness of an mTOR-based
systemic therapy regimen in advanced, metaplastic and
nonmetaplastic triple-negative breast cancer. Oncologist.
23:1300–1309. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rakha EA, Coimbra NDM, Hodi Z, Juneinah E,
Ellis IO and Lee AHS: Immunoprofile of metaplastic carcinomas of
the breast. Histopathology. 70:975–985. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim I, Rajamanickam V, Bernard B, Chun B,
Wu Y, Martel M, Sun Z, Redmond WL, Sanchez K, Basho R, et al: A
case series of metastatic metaplastic breast carcinoma treated with
anti-PD-1 therapy. Front Oncol. 11:6352372021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Abada E, Kim S, Dozier K, Fehmi O, Jang H,
Fehmi Z and Bandyopadhyay S: Estrogen receptor status has no
prognostic relevance in metaplastic breast carcinoma. Cancer Treat
Res Commun. 33:1006302022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang S, Hu J, Zhang Y, Shen J, Dong F,
Zhang X, Lu C and Shang D: Presentation and survival by hormonal
receptor status in metaplastic breast cancer: A propensity
score-matched analysis. Breast. 60:168–176. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Samoon Z, Beg M, Idress R and Jabbar AA:
Survival and treatment outcomes of metaplastic breast carcinoma:
Single tertiary care center experience in Pakistan. Indian J
Cancer. 56:124–129. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hu J, Lang R, Zhao W, Jia Y, Tong Z and
Shi Y: The mixed subtype has a worse prognosis than other
histological subtypes: A retrospective analysis of 217 patients
with metaplastic breast cancer. Breast Cancer Res Treat. 200:23–36.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee H, Jung SY, Ro JY, Kwon Y, Sohn JH,
Park IH, Lee KS, Lee S, Kim SW, Kang HS, et al: Metaplastic breast
cancer: Clinicopathological features and its prognosis. J Clin
Pathol. 65:441–446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chartier S, Brochard C, Martinat C, Coussy
F, Feron JG, Kirova Y, Cottu P, Marchiò C and Vincent-Salomon A:
TROP2, androgen receptor, and PD-L1 status in histological subtypes
of high-grade metaplastic breast carcinomas. Histopathology.
82:664–671. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yigit S, Pehlivan FS, Evcim G and Etit D:
Clinicopathologic features of the mixed epithelial and mesenchymal
type metaplastic breast carcinoma with myoepithelial
differentiation in a subset of six cases. Pathol Res Pract.
208:147–150. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Takala S, Heikkilä P, Nevanlinna H,
Blomqvist C and Mattson J: Metaplastic carcinoma of the breast:
Prognosis and response to systemic treatment in metastatic disease.
Breast J. 25:418–424. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Moreno AC, Lin YH, Bedrosian I, Shen Y,
Babiera GV and Shaitelman SF: Outcomes after treatment of
metaplastic versus other breast cancer subtypes. J Cancer.
11:1341–1350. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Youssef I, Lee A, Kukunoor S, Taiwo E,
Luhrs CA and Schreiber D: Patterns of care and survival of
metastatic metaplastic breast cancer patients. Cureus.
12:e103392020.PubMed/NCBI
|
|
41
|
Rayson D, Adjei AA, Suman VJ, Wold LE and
Ingle JN: Metaplastic breast cancer: Prognosis and response to
systemic therapy. Ann Oncol. 10:413–419. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen IC, Lin CH, Huang CS, Lien HC, Hsu C,
Kuo WH, Lu YS and Cheng AL: Lack of efficacy to systemic
chemotherapy for treatment of metaplastic carcinoma of the breast
in the modern era. Breast Cancer Res Treat. 130:345–351. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Noro A, Ishitobi M, Hanamura N, Kashikura
Y, Yamashita M, Kozuka Y, Saito K, Mizuno T and Ogawa T: A case of
metaplastic squamous cell carcinoma of the breast that showed a
pathological complete response after neoadjuvant chemotherapy with
weekly paclitaxel. Am J Case Rep. 23:e9350352022.PubMed/NCBI
|
|
44
|
Cortes J, Cescon DW, Rugo HS, Nowecki Z,
Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, et
al: Pembrolizumab plus chemotherapy versus placebo plus
chemotherapy for previously untreated locally recurrent inoperable
or metastatic triple-negative breast cancer (KEYNOTE-355): A
randomised, placebo-controlled, double-blind, phase 3 clinical
trial. Lancet. 396:1817–1828. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
FDA, . FDA grants accelerated approval to
pembrolizumab for locally recurrent unresectable or metastatic
triple negative breast cancer. 2020.
|
|
46
|
Joneja U, Vranic S, Swensen J, Feldman R,
Chen W, Kimbrough J, Xiao N, Reddy S, Palazzo J and Gatalica Z:
Comprehensive profiling of metaplastic breast carcinomas reveals
frequent overexpression of programmed death-ligand 1. J Clin
Pathol. 70:255–259. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ladwa A, Elghawy O, Schroen A, Abernathy
K, Schlefman J and Dillon P: Complete response of triple-negative
metaplastic carcinoma of the breast using pembrolizumab. Case Rep
Oncol. 16:1129–1135. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gul A, Alberty-Oller JJ, Sandhu J,
Ayala-Bustamante E and Adams S: A case of pathologic complete
response to neoadjuvant chemotherapy and pembrolizumab in
metaplastic breast cancer. JCO Precis Oncol. 7:e22005062023.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Gorshein E, Matsuda K, Riedlinger G, Sokol
L, Rodriguez-Rodriguez L, Eladoumikdachi F, Grandhi M, Ganesan S,
Toppmeyer DL, Potdevin L, et al: Durable response to PD1 inhibitor
pembrolizumab in a metastatic, metaplastic breast cancer. Case Rep
Oncol. 14:931–937. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Fu Y, Liu J and Jiang Y: Partial response
after toripalimab plus anlotinib for advanced metaplastic breast
carcinoma: A case report. Front Endocrinol (Lausanne).
13:8107472022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Adams S, Othus M, Patel SP, Miller KD,
Chugh R, Schuetze SM, Chamberlin MD, Haley BJ, Storniolo AMV, Reddy
MP, et al: A Multicenter phase II trial of ipilimumab and nivolumab
in unresectable or metastatic metaplastic breast cancer: Cohort 36
of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART,
SWOG S1609). Clin Cancer Res. 28:271–278. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Corso G, Marabelli M, Calvello M, Gandini
S, Risti M, Feroce I, Mannucci S, Girardi A, De Scalzi AM, Magnoni
F, et al: Germline pathogenic variants in metaplastic breast cancer
patients and the emerging role of the BRCA1 gene. Eur J Hum Genet.
31:1275–1282. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lane R, Yan F, Higgins D and Agarwal G:
Synchronous metaplastic breast carcinoma and lung adenocarcinoma: A
rare case and review of the literature. BMJ Case Rep.
13:e2324212020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Rugo HS, Bardia A, Tolaney SM, Arteaga C,
Cortes J, Sohn J, Marmé F, Hong Q, Delaney RJ, Hafeez A, et al:
TROPiCS-02: A phase III study investigating sacituzumab govitecan
in the treatment of HR+/HER2-metastatic breast cancer. Future
Oncol. 16:705–715. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Bardia A, Hurvitz SA, Tolaney SM, Loirat
D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak
AB, et al: Sacituzumab govitecan in metastatic triple-negative
breast cancer. N Engl J Med. 384:1529–1541. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Püsküllüoğlu M, Rudzińska A and
Pacholczak-Madej R: Antibody-drug conjugates in HER-2 negative
breast cancers with poor prognosis. Biochim Biophys Acta Rev
Cancer. 1878:1889912023. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Reddy TP, Rosato RR, Li X, Moulder S,
Piwnica-Worms H and Chang JC: A comprehensive overview of
metaplastic breast cancer: Clinical features and molecular
aberrations. Breast Cancer Res. 22:1212020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Hayes MJ, Thomas D, Emmons A, Giordano TJ
and Kleer CG: Genetic changes of Wnt pathway genes are common
events in metaplastic carcinomas of the breast. Clin Cancer Res.
14:4038–4044. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Esbah O, Turkoz FP, Turker I, Durnali A,
Ekinci AS, Bal O, Sonmez OU, Budakoglu B, Arslan UY and Oksuzoglu
B: Metaplastic breast carcinoma: Case series and review of the
literature. Asian Pac J Cancer Prev. 13:4645–4649. 2012. View Article : Google Scholar : PubMed/NCBI
|
